Verisante Technology has received the Conformite Europeenne (CE) mark for its Verisante Aura, used to diagnose skin cancers.
Aura is a non-invasive optical system used to identify suspected skin lesions for diagnosis as either skin cancer or a benign disorder within two seconds.
The move follows the six year clinical study at the Skin Care Centre at Vancouver General Hospital, British Columbia, where Verisante Aura was used to collect data on more than 1,000 lesions.
Vancouver General Hospital Skin Care Centre director Harvey Lui said Verisante Aura is a unique tool that can help doctors to detect skin cancers efficiently.
"With the rising incidence of all types of skin cancers, innovative tools such as the Aura, which can potentially be used by general practitioners to evaluate suspicious skin lesions quickly and accurately, will become increasingly important to the healthcare system," Lui added.
The company plans to launch the device in the EU region, Germany, Austria and Switzerland.